Abstract
Objective: To identify easily accessible biomarkers for mucosal inflammation and disease progression in chronic rhinosinusitis (CRS) we assessed levels of inflammatory mediators in nasal secretions and urine related to nasal polyp (NP) severity or Aspirin Exacerbated Respiratory Disease (AERD).
Methods: Samples were collected from patients with CRS without NP (CRSsNP) or with (CRSwNP) and/or AERD and controls. CRSwNP was further subdivided based on nasal polyp scores; NP-low (NPS≤4) or NP-high (NPS≥5). Nasal secretion and urine samples were analyzed for lipid mediators and cytokines. Mediator levels were compared between subgroups and correlated to clinical parameters as exhaled nitric oxide (FeNO), blood eosinophil counts and smell test score.
Results: Nasal secretions from patients with CRSwNP-AERD had elevated levels of LTE4, resolvin (Rv)D1 and IL-6 and NP-high had increased levels of PGD2, both in comparison to NP-low. Cytokines featured generally low detection in nasal secretions, although IL-13 was exclusively detectable in NP-high and CRSwNP-AERD. The PGD2 metabolite 11β-PGF2α was elevated in urine from NP-high and CRSwNP-AERD as opposed to CRSsNP and correlated with smell test score. Nasal LTE4 and RvD1 was correlated to lowered smell test score as well as to elevated FeNO.
Conclusion: Patients with different nasal polyp severity and /or AERD may be distinguished by altered levels of lipid mediators in nasal mucosa in readily available and non-invasively collected nasal secretions, and changes in lipid mediator levels seems related to the degree of smell loss and FeNO.
Footnotes
Cite this article as ERJ Open Research 2022; 8: Suppl. 8, 57.
This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.
This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
